35 results about "Cmv infections" patented technology

Immunogenic compositions and prophylactic or therapeutic vaccines for use in protecting and treating against human cytomegalovirus (CMV) are disclosed. Subunit vaccines comprising a human CMV protein complex comprising pUL128 or pUL130, and nucleic acid vaccines comprising at least one nucleic acid encoding a CMV protein complex comprising pUL128 or pUL130 are described. Also disclosed are therapeutic antibodies reactive against a CMV protein complex comprising pUL128 or pUL130, as well as methods for screening compounds that inhibit CMV infection of epithelial and endothelial cells, methods for immunizing a subject against CMV infection, methods for determining the capability of neutralizing antibodies to inhibit human CMV infection of cell types other than fibroblasts, and methods of diminishing an CMV infection.

The invention provides an immunogen composition containing polypeptide derived from cytomegalovirus (CMV) and a use method thereof. The composition comprises (a) at least one of CMV pp65 and polypeptide derived from CMV IE-1 polypeptide; and (b) polypeptide selected from groups formed by polypeptides derived from CMV VGLB, CMV VPAP and CMV p100 polypeptides, and the combination thereof. The immunogen composition of the invention can effectively activate CMV resistant immunoreaction after confirmation. Live virus, cells infected by CMV, and full-length CMV cells are not used in a polypeptide library so that no infection, mmunosuppression action, immunologic tolerance and the like are caused.

The invention discloses a chemiluminescence immunoassay analysis diagnosing test kit and a preparing method thereof for detecting cytomegalovirus IgG antibody. The test kit includes positive and negative reference substance, solid-phase carrier, labeled antigen, enzyme-labeled antibody, chemiluminescence zymolyte liquid and condensed washing liquid. The test kit has great significance in screening diagnosis and monitoring for pre-pregnancy and early-pregnancy infection of childbearing women as well as CMV infection diagnosis of high risk group (such as tumour, organ transplanting, HIV and the like ).

The invention provides an expansion culture method of CD8 T cells. The CD8 T cells are subjected to induced expansion culture in the presence of the following substances: K3EC cells and a peptide-fragment overlapping library of a target antigen; and the K3EC cells are K562 engineering cells expressing CD2 ligands CD58, NKG2D ligands MICA/B and CD137 ligands CD137L and are used for providing costimulatory receptor second signals activating the CD8 T cells, and the peptide-fragment overlapping library of the target antigen is used for providing T cell receptor (TCR) first signals activating theCD8 T cells. According to the method, quick and efficient expansion of the antigen (CMV-pp65) specific CD8 T cells; and the CD8 T cells obtained through expansion have high clinical application valuein prevention and treatment of CMV infection and treatment of CMV-related cancers.

A method of designing a new anti-CMV drug is disclosed. In one embodiment, the invention comprises (a) analyzing the binding of glycoprotein O to a glycoprotein O receptor and (b) designing a candidate drug that would competitively interfere with glycoprotein O binding to glycoprotein O receptor and (c) showing that the candidate drug competitively inhibits glycoprotein O binding to glycoprotein O receptor. A method of screening anti-CMV drugs, a vaccine effective to diminish CMV infection, and a method of diminishing CMV infection are also disclosed.

Antibodies to human Cytomegalovirus (CMV) gB protein have been isolated from human B cells. The affinities of these antibodies are higher than the best previously reported antibodies. Since high affinity is critical to prevention of virus transfer across the placenta, the invention antibodies are useful as therapeutic and prophylactic agents to prevent or ameliorate effects on the fetus of CMV infection during pregnancy.

The invention relates to a kit and a method for detecting CMV infection in a trace biological sample of an eye, and relates to a molecular detection technology for eye viral infections, in particularto a method for extracting DNA from the trace biological sample, wherein the trace biological sample refers to a liquid sample with a volume not exceeding 10mu l-200mu l or a solid sample with a volume not exceeding 1mm<3>. By use of the extracted DNA as a PCR detection template, the eye viral infections can be detected with an accuracy of 80% or more, and the method provides a reliable basis forsubsequent appropriate treatment methods and reduces the blindness of the treatment methods.

The present invention relates to the field of cytomegalovirus (CMV) infection. In particular the present invention relates to highly specific immunotoxins useful in treating diseases related to CMV infection. CMV encodes chemokine receptors that undergo constitutive internalization. Thus CMV infected cells can be targeted specifically with immunotoxins with high affinity to CMV encoded constitutively internalizing receptors. This will ensure efficient uptake of the immunotoxin by the CMV infected cell, and thereby ensure the death of the infected cell with a minimum of unwanted toxicity and side effects. Furthermore, the invention relates to a way of inhibiting CMV replication and/or growth by using immunotoxins by targeting constitutively internalizing CMV encoded receptors.

Provided herein are immunogenic polypeptides, compositions, and methods related to the development of CMV-specific prophylactic and/or therapeutic immunotherapy based on T cell epitopes (e.g., CMV epitopes) that are recognized by cytotoxic T cells (CTLs) and can be employed in the prevention and/or treatment of CMV infection, reactivation, and/or disease (e.g., CMV-associated end organ disease), especially in solid organ transplant recipients.

The present invention provides novel inhibitors of inflammation and methods for treating inflammation by using these inhibitors. More specifically, the present invention provides transcription inhibitors, i.e., peptide fragments derived from internal regions of the Cytomegalovirus (CMV) IE2 protein that can inhibit production of inflammatory cytokines, e.g., Interleukin 1 beta(IFN-1β) and the methods for treating inflammatory diseases and CMV infection and related disorders, by using the IE2 fragments. An pharmaceutical composition comprising the transcription inhibitor are also provided.

The invention relates to a RNA interference sequence targeting a cucumber mosaic virus, an expression vector thereof and application. The cucumber mosaic virus targeted RNA interference sequence is double-stranded RNA, is composed of a sense strand and an antisense strand, and is an interference sequence GT1 of a GT1 gene specifically targeting CMV-1a protein, or an interference sequence GT2 of a GT2 gene specifically targeting CMV-1a protein, or an interference sequence GT3 of a GT3 gene specifically targeting CMV-2a protein, or an interference sequence GT4 of a GT4 gene specifically targeting CMV-2a protein, or an interference sequence GT5 of a GT5 gene specifically targeting CMV-CP protein, or an interference sequence GT16 of a GT6 gene specifically targeting CMV-MP protein. The double-stranded RNA interference sequence is used for degrading target messenger RNA, reducing expression of target protein, effectively silencing CMV genes and controlling CMV infection, and has the characteristic of environmental friendliness and high commercial application value.

The present disclosure provides a method for inhibiting cytomegalovirus (CMV) replication in a cell infected with CMV, the method comprising contacting the cell with a bisbenzimidazole compound. The present disclosure provides a method of treating a CMV infection in an individual, the method comprising administering to the individual an effective amount of a bisbenzimidazole compound.

The present invention relates the field of CMV and CMV related diseases. Using a powerful rat model of CMV infection of the embryonic brain, the inventors have looked for the existence of postnatal neurological and neurosensory manifestations, and have tested whether the early pharmacological targeting of microglia during pregnancy impacts on postnatal phenotypes. Particularly, the inventors tested the clodronate and the doxycycline and showed that these compounds improve the postnatal outcome of the baby. Thus, the invention relates to a compound which modifies the microglia for use in the treatment of CMV related diseases in a subject in need thereof.

The invention discloses a primer pair for identifying capsicum CMV infection resistance and application of the primer pair. According to the primer pair, a forward primer is as shown in SEQ ID NO.1, and a reverse primer is as shown in SEQ ID NO.2. PCR amplification is performed on a marker by utilizing capsicum genome DNA; if a molecular marker strip of 214 bp exists, the plant is a disease-resistant plant; if a molecular marker strip of 220bp exists, the plant is a diseased plant. By utilizing the marker, an anti-CMV breeding material can be accurately and efficiently screened, offspring single plants carrying resistance genes can be efficiently and accurately screened in hybridization and backcross populations, and compared with conventional anti-CMV breeding, creation of the anti-CMV breeding material and breeding of new varieties can be remarkably accelerated.